

Luye Pharma & DCH Auriga put focus on mental healthcare in Singapore

14 December 2022 | News

Luye Pharma has granted DCH Auriga Singapore exclusive distribution and marketing rights for Seroquel and Seroquel XR in Singapore

Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, has entered a distribution partnership with DCH Auriga, an Asian-based integrated market management provider specializing in healthcare.

According to the terms of the agreement, Luye Pharma grants Auriga exclusive distribution and marketing rights for Seroquel (quetiapine fumarate, immediate release formulation) and Seroquel XR (extended release formulation) in Singapore.

Seroquel used for the treatment of schizophrenia and bipolar disorder, is recommended by several authorised guidelines around the world.

The agreement was signed at Singapore, with both parties officially marking the start of the partnership and further pledging to make joint efforts to raise awareness of mental health issues as part of the "We Care About Mental Health" APAC initiative. The regional initiative aims to raise awareness of mental health issues, supporting patients, physicians and health systems in meeting patient needs.

Mental disorders such as bipolar disorder, schizophrenia, depression and anxiety have become major public health problems affecting global public health. According to survey data from Singapore, the prevalence rate of common mental diseases is 13.9% among local adults aged 18 and above, showing an increasing trend; and the prevalence of bipolar disorder and schizophrenia are about 1.6% and 1%, respectively.